Trial Will Test Rigosertib for Skin Cancer in RDEB

Trial Will Test Rigosertib for Skin Cancer in RDEB

302092

Trial Will Test Rigosertib for Skin Cancer in RDEB

An open-label, Phase 1/2 clinical trial will evaluate the safety and efficacy of rigosertib in treating recessive dystrophic epidermolysis bullosa (RDEB) in people with an aggressive skin cancer called cutaneous squamous cell carcinoma (SCC). RDEB is known to bring a higher risk of developing SCC, which can be life-threatening. The study is sponsored by the department of dermatology and cutaneous biology at Thomas Jefferson University, Philadelphia, Pennsylvania, and supported by DEBRA International, a global epidermolysis bullosa…

You must be logged in to read/download the full post.